Throughout the past 20 yr, substantial epidemiologic evidence has emerged suggesting that suboptimal vitamin K status can have an adverse effect on BMD and increase the risk of bone fracture. However, only recently have prospective clinical trials been conducted to determine whether vitamin K plays a role in the prevention of bone loss. In the current issue of Journal of Bone and Mineral Research, Binkley et al.(1) report on the results of a double-blind placebo-controlled trial of vitamin K supplementation in postmenopausal women.

Vitamin K was discovered in 1935 by the Danish biochemist Henrik Dam, who was studying dietary deficiency diseases in chickens. When fed a diet free of fat and cholesterol, the chickens developed intramuscular hemorrhages and uncontrollable bleeding. Dam, with Edward Doisy, isolated the dietary substance required for blood clotting and called it the “Koagulation Vitamin,” or vitamin K. Soon thereafter, inactive prothrombin was shown to be the cause of the bleeding abnormality observed in vitamin K deficiency.(2,3) Almost simultaneously, dicoumarol was identified as the causative agent of a hemorrhagic disease in cattle fed spoiled sweet clover hay, and its derivative, warfarin, was established as a potent anticoagulant.(4) The mechanism of action of vitamin K remained unknown until 1974 when the modified amino acid, γ-carboxyglutamic acid (Gla), was identified in normal prothrombin.(5,6) The formation of Gla occurs through a unique vitamin K–dependent post-translational carboxylation of specific peptide-bound glutamate residues in a process that is inhibited by warfarin.(7) In the mid-1970s, fetal warfarin syndrome was described. Affected infants manifested bony malformations, stippled epiphyses, and nasal hypoplasia. Mothers of infants with these characteristics were found to have received oral anticoagulation therapy during the first trimester of pregnancy.(8) These findings led to the question of whether vitamin K nutrition or warfarin therapy plays a role in skeletal health and to the discovery of osteocalcin and other vitamin K–dependent proteins in bone.(9–11)

Vitamin K occurs as either phylloquinone (K1) or menaquinones (MK-n). All forms share a common structure, 2-methyl-1,4-napthoquinone, which is necessary for participation in carboxylation, but differ in the number and degree of saturation of isoprenyl side chains.(12) The major dietary form of the vitamin is phylloquinone, which is present in dark green vegetables and certain plant oils. Long-chain menaquinones can be found in fermented foods such as cheeses or in natto, a soybean product popular in Japan. The menaquinones are synthesized by gut bacteria but do not contribute appreciably to vitamin K status in humans.(13) Whereas there is no evidence of change in coagulation times in healthy adults with mild vitamin K deficiency, usual dietary intakes of vitamin K do not support complete carboxylation of osteocalcin.(14) Vitamin K restriction results in an increase in serum uncarboxylated osteocalcin, and supplementation for 2 wk with 400 μg/d K1—equivalent to 2 cups of cooked broccoli—results in a 40% decrease in uncarboxylated osteocalcin.(15) In fact, uncarboxylated osteocalcin (ucOC) in serum is the most sensitive indicator of overall vitamin K nutritional status. It should be pointed out that, because the amount of ucOC is highly correlated to total OC and total osteocalcin reflects osteoblastic activity, the ucOC fraction is expressed as %ucOC.

So, what are the implications of vitamin K status for bone health? Papers regarding direct effects of warfarin therapy on BMD in humans are conflicting. Increased fracture risk has been associated with anticoagulant therapy but primarily in studies of the elderly in a long-term care setting.(16–18) Such studies are problematic because of frequent confounding comorbidities. Within the last 20 yr, a preponderance of studies has advanced the notion that low dietary phylloquinone intake, as assessed by food frequency questionnaires, low circulating vitamin K levels, or high %ucOC is associated with low BMD and increased hip fracture risk.(19) Although most of these studies were relatively small, they have been corroborated by several larger ones. In the Nurses Health Study, risk for hip fracture was significantly greater in the lowest quintile of vitamin K intake; however, a relatively narrow range of vitamin K intake was noted in the entire cohort.(20) In the Framingham Offspring Study, dietary phylloquinone intake was associated with total hip and lumbar spine BMD in women but not in men.(21) All of these studies are hampered by the inability to separate the effects of a single nutrient from those of an overall healthy diet. In fact, high fruit and vegetable consumption was associated with less age-related bone loss in the Framingham Heart Study.(22)

Finally, pharmacologic doses of MK4 (menatetrenone) have been studied in Japan as a treatment for osteoporosis. This is derived from the observation that the incidence of osteoporotic fracture is relatively lower in regions of the country where dietary intake of natto is high.(23) There are also some suggestions that the anti-osteoporotic effects of MK4 are independent of γ-carboxylation.(24) In a recent meta-analysis of 13 small randomized controlled trials with data on bone loss, the authors concluded that supplementation with either MK4 or K1 has a positive effect on BMD. Further analysis, including only the trials that provided both BMD and fracture data, concluded that supplementation with 45 mg/d of menatetrenone was associated with increased BMD and reduced fracture incidence.(25) However, the authors of the meta-analysis raised concerns that the trials were often poorly designed. Published commentary have also questioned the findings.(1,19,26–28)

Results of several placebo-controlled clinical trials of vitamin K1 are now being reported. One(29) showed a modest positive effect of 200 μg/d of K1 for 2 yr on BMD at the distal radius but not at any other skeletal site. Another provided 5000 μg/d of K1 for 2 yr but did not find a beneficial effect on bone turnover markers or BMD at any site, including the distal radius.(30)

In the well-designed study in this issue of JBMR, Binkley et al. supplemented 381 postmenopausal women with either 1 mg K1 daily, 15 mg menatetrenone three times a day, or corresponding placebos for 1 yr. All were provided calcium and vitamin D. The dosing reflects the previous study of Binkley et al.,(31) in which 1 mg/d of phylloquinone was required to fully carboxylate osteocalcin. A particular strength of this study is the head-to head comparison of optimal doses of K1 and MK4. The vast majority of studies of MK4 have been in Japanese subjects, and its potential efficacy in Western societies has not been explored. To maximize the potential benefit of vitamin K, Binkley et al. selected only women who were not vitamin K replete as defined by an elevated %ucOC. Outcome measures included BMD of the lumbar spine and proximal femur as well as hip geometry and bone turnover markers. In both treatment groups, %ucOC decreased by 60% after 1 mo of supplementation and remained stable thereafter, verifying compliance, effectiveness of dose, and inadequate vitamin K nutritional status at baseline. Compared with placebo, there were no differences in bone-specific alkaline phosphatase or N-telopeptide (NTX), nor were there differences in BMD of the lumbar spine or total femur in either treatment group. These results are similar to those observed by Booth et al.(26) in another, recently published, 3-yr duration placebo-controlled trial of 500 μg/d of K1.

It has been suggested that vitamin K may improve bone quality and microarchitectural bone strength. For example, femoral neck width was significantly greater in women receiving MK4, 45 mg/d for 3 yr, than in a placebo group.(32) Addressing these considerations, this study observed similar speed of sound or broadband ultrasound attenuation, femoral neck BMC, BMD, area, diameter, cross-sectional area, cross-sectional moment of inertia, length, and strength index across all study groups.

The authors acknowledge limitations in their study such as the relatively short 1-yr duration, the inclusion of only healthy women, and the lack of fracture incidence or reduction as outcome measures. It would seem from the lack of an effect that extremely large numbers of subjects would be necessary to detect differences in fracture rate. In an as yet unpublished trial carried out by Eisai in 3000 elderly subjects, there was no benefit of 3 yr of 45 mg/d MK4 plus calcium in subjects without a history of fracture, and only a small effect in those with a history of more than five vertebral fractures at baseline.(33)

In summary, the absence of change in bone turnover markers or BMD in this and other studies suggests that it is unlikely that vitamin K supplementation will serve to prevent fractures in individuals who are receiving calcium and vitamin D supplementation.

Nevertheless, investigators in the bone field cannot forget about vitamin K yet. Last year, the group led by Gerard Karsenty published evidence that osteocalcin is involved in the endocrine regulation of energy metabolism in mice.(34) This is a novel and exciting concept that challenges much of what we know about osteocalcin. Even more provocative are their data suggesting that, with respect to regulation of energy homeostasis, the active form of osteocalcin is uncarboxylated and that the carboxylated form is inactive. Animals with higher levels of uncarboxylated osteocalcin were protected from obesity and glucose intolerance. To determine whether this effect is evident in humans as well, Yoshida et al.(35) recently re-examined the available data in their study of the effect of vitamin K on bone loss, finding that supplementation with 500 g of phylloquinone daily for 36 mo had a protective effect on the progression of insulin resistance in older men. Because increased vitamin K intake decreases uncarboxylated osteocalcin, these results suggest a possible species difference between humans and mice in this regard. These data clearly indicate the need for further research and better understanding of the relationship between osteocalcin, its carboxylation, and vitamin K.


  1. Top of page
  • 1
    Binkley NC, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J 2009 Vitamin K Treatment Reduces Undercarboxylated Osteocalcin But Does Not Alter Bone Turnover, Density or Geometry in Healthy Postmenopausal North American Women. J Bone Miner Res 24: 000000.
  • 2
    Dam H 1935 The antihaemorrhagic vitamin of the chick. Biochemistry 29: 12731285.
  • 3
    Binkley SB, MacCorquodale DW, Thayer SA, Doisy EA 1939 The isolation of vitamin K1. J Biol Chem 130: 219234.
  • 4
    Campbell HA, Roberts WL, Smith WK, Link KP 1940 Studies on the hemorrhagic sweet clover disease. I. The preparation of hemorrhafic concentrates. J Biol Chem 136: 4755.
  • 5
    Stenflo J, Fernlund P, Egan W, Roepstorff P 1974 Vitamin K-dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 71: 27302733.
  • 6
    Nelsestuen GL, Zytkovicz TH, Howard JB 1974 The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249: 63476350.
  • 7
    Suttie JW 1993 Synthesis of vitamin K-dependent proteins. FASEB J 7: 445452.
  • 8
    Pettifor JM, Benson R 1975 Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 86: 459462.
  • 9
    Hauschka PV, Lian JB, Gallop PM 1975 Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72: 39253929.
  • 10
    Price PA, Urist MR, Otawara Y 1983 Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 117: 765771.
  • 11
    Viegas CSB, Simes DC, Laize V, Williamson MK, Price PA, Cancela ML 2008 Gla-rich protein (GRP), a new vitamin K–dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem 283: 3665536664.
  • 12
    Shearer MJ, Newman P 2008 Metabolism and cell biology of vitamin K. Thromb Haemost 100: 530547.
  • 13
    Suttie JW 1995 The importance of menaquinones in human nutrition. Annu Rev Nutr 15: 399417.
  • 14
    Sokoll LJ, Sadowski JA 1996 Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr 63: 566573.
  • 15
    Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA 1997 Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma- carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr 65: 779784.
  • 16
    Szulc P, Chapuy MC, Meunier PJ, Delmas PD 1993 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91: 17691774.
  • 17
    Szulc P, Chapuy MC, Meunier PJ, Delmas PD 1996 Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study. Bone 18: 487488.
  • 18
    Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ 1999 Changes in bone density after exposure to oral anticoagulants: A meta-analysis. Osteoporos Int 9: 441448.
  • 19
    Pearson DA 2007 Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract 22: 517544.
  • 20
    Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA 1999 Vitamin K intake and hip fractures in women: A prospective study. Am J Clin Nutr 69: 7479.
  • 21
    Booth S, Broe K, Gagnon D, Tucker KL, Hannan MT, McLean RR, Dawson-Hughes B, Wilson PW, Cupples LA, Kiel DP 2003 Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr 77: 512516.
  • 22
    Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PWF, Kiel DP 1999 Potassium, magnesium and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 69: 727736.
  • 23
    Ikeda Y, Iki M, Morita A, Kajita E, Kagamimori S, Kagawa Y, Yoneshimay H 2006 Intake of fermented soybeans, natto, Is associated with reduced bone loss in postmenopausal women: Japanese population-based Osteoporosis (JPOS) Study. J Nutr 136: 13231328.
  • 24
    Nanke Y, Kotake S, Ninomiya T 2005 Geranylgeranylacetone inhibits formation and function of human osteoclasts and prevents bone loss in tail-suspended rats and ovariectomized rats. Calcif Tissue Int 77: 376385.
  • 25
    Cockayne S, Adamson J, Lanhamp-New S, Shearer MJ, Gilbody S, Torgerson DJ 2006 vitamin K and the prevention of fractures: Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166: 12561261.
  • 26
    Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B 2008 Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 93: 12171223.
  • 27
    Tamura T, Morgan SL, Takimoto H 2007 Vitamin K and the prevention of fractures. Arch Intern Med. 167: 94.
  • 28
    Halbekath JM, Schenk S, von Maxen A, Meyer G, Mühlhauser I 2007 Prevention of hip fractures: Concern about validity of trials. Arch Intern Med. 167: 513514.
  • 29
    Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ 2007 Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22: 509519.
  • 30
    Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R 2008 Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): A randomized controlled trial. PLoS Med 5: e196.
  • 31
    Binkley NC, Krueger DC, Foley AL, Engelke JA, Suttie JW 2000 Vitamin K supplementation reduces serum under gamma-carboxylated osteocalcin concentration in healthy adults. Am J Clin Nutr 72: 15231528.
  • 32
    Knapen MHJ, Schurgers LJ, Vermeer C 2007 Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18: 963972.
  • 33
    Eisai 2005 Eisai announces the intermediate analysis of anti-osteoporosis treatment post-marketing research to investigate the benefits of menatetreone as part of the Ministry of Health, Labor, and Welfare's pharmacoepidemiological drug review program. Available at Accessed October 5, 2007.
  • 34
    Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang A, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G 2007 Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456469.
  • 35
    Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, Gundberg C, Dawson-Hughes B, Dallal G, Booth SL 2008 Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care 31: 20922096.